BridgeBio
BBIO
$81.50
-1.74%
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases, with a pipeline spanning Mendelian disorders, oncology, and gene therapy. Its lead product, Attruby (acoramidis), is an orally administered small molecule for transthyretin amyloid cardiomyopathy (ATTR-CM), positioning the company as a key player in the precision medicine space. The current investor narrative centers on the commercial ramp of Attruby, promising pipeline catalysts such as the achondroplasia program, and the path to profitability, with recent news highlighting strong trial data and analyst optimism despite ongoing net losses.…
BBIO
BridgeBio
$81.50
Related headlines
Investment Opinion: Should I buy BBIO Today?
Based on the analysis, BBIO is rated a Buy, supported by strong revenue growth, a robust pipeline, and a consensus Strong Buy rating with an average target price of $108.43, implying 33% upside. The thesis is that Attruby's commercial success and upcoming catalysts will drive sustained growth, justifying the premium valuation. However, investors should be aware of the high risk due to unprofitability and competitive pressures.
Key evidence includes: Q1 2026 revenue growth of 66.8% YoY, gross margin of 94.6%, and a forward PE of 532x (not meaningful due to losses). The PS ratio of 30.05x is above the industry average, but the company's growth rate and market opportunity support a premium. Analysts estimate revenue of $4.64B for the next fiscal year, implying a forward PS of about 3.25x, which is more reasonable. The stock's 1-year return of +62.25% outperformed the S&P 500's +20.48%, demonstrating strong momentum.
The biggest risks are a slowdown in Attruby sales, failure of the achondroplasia program, and continued cash burn. If revenue growth falls below 30% or the FDA filing is delayed, the rating would be downgraded to Hold. Conversely, if Attruby sales exceed expectations and the pipeline advances, the stock could reach the high target of $157. Overall, BBIO is fairly valued relative to its growth potential, but investors should monitor execution closely.
Sign up to view all
BBIO 12-Month Price Forecast
The AI assessment is bullish on BBIO, driven by robust revenue growth and a clear path to profitability through Attruby's commercial success. The high gross margin and improving net margin trend suggest operating leverage is taking effect. However, the medium confidence reflects the elevated valuation and binary risks from pipeline events. If Attruby sales continue to exceed expectations and the achondroplasia program advances without setbacks, the stock could re-rate higher. Conversely, any negative surprises could lead to a sharp correction, so monitoring quarterly results and regulatory milestones is crucial.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on BridgeBio's 12-month outlook, with a consensus price target around $108.43 and implied upside of +33.0% versus the current price.
Average Target
$108.43
0 analysts
Implied Upside
+33.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$80 - $157
Analyst target range
Recent institutional ratings show a consistent bullish stance, with firms like HC Wainwright, Mizuho, and Morgan Stanley maintaining Buy/Outperform ratings, though Raymond James downgraded to Market Perform in May 2026. The high target of $157.00 implies a 92.6% upside, likely assuming successful FDA approval for the achondroplasia program and continued Attruby market share gains. The low target of $80.00 is near the current price, suggesting downside is limited but not negligible, possibly pricing in slower-than-expected sales growth or competitive pressures. Overall, the analyst community is highly optimistic, but the wide target range reflects the inherent volatility and binary outcomes typical of biotech stocks.
Bulls vs Bears: BBIO Investment Factors
BridgeBio presents a compelling growth story driven by Attruby's commercial success and a promising pipeline, but the stock trades at a premium valuation that leaves little room for disappointment. The bull case is supported by strong revenue growth, high gross margins, and analyst optimism, while the bear case hinges on persistent losses, high cash burn, and competitive pressures. Currently, the bull side has stronger evidence given the accelerating revenue and clear catalysts, but the single most important tension is whether Attruby's sales growth can sustain the current valuation multiple—if growth decelerates, the stock could face significant downside despite its strong fundamentals.
Bullish
- Attruby Sales Driving 66.8% Revenue Growth: Q1 2026 revenue surged to $194.5M, up 66.8% YoY, with Attruby contributing $180.6M in product sales. This demonstrates strong commercial uptake and validates the drug's market potential, positioning the company for continued top-line expansion.
- High Gross Margin of 94.6%: Gross margin reached 94.6% in Q1 2026, reflecting the low cost of goods for oral small molecules. This provides a solid foundation for future profitability as revenue scales, with each incremental dollar contributing significantly to covering operating expenses.
- Analyst Consensus Strong Buy with 33% Upside: With 21 analysts, the consensus rating is Strong Buy and the average target price is $108.43, implying a 33% upside from the current $81.50. The high target of $157 suggests potential for 92.6% gains if pipeline catalysts succeed, reflecting significant optimism.
- Pipeline Catalyst: Achondroplasia Program: Positive Phase 3 trial data for the achondroplasia drug, with FDA filing planned in 2026, could open a new revenue stream. This binary catalyst has the potential to substantially increase the company's valuation if approved, as seen in the stock's recent surge to near 52-week highs.
Bearish
- Persistent Net Losses and Cash Burn: Q1 2026 net loss was $164.0M, with negative free cash flow of -$454M TTM. The company remains unprofitable, and continued losses require ongoing capital raises, which could dilute shareholders if the market turns risk-off.
- Extremely High Valuation at 30x Sales: The PS ratio of 30.05x is significantly above the biotech industry average of 5-10x, pricing in aggressive growth expectations. Any slowdown in Attruby sales or pipeline setbacks could trigger a sharp multiple contraction, as seen in the stock's 20.25% max drawdown.
- Heavy R&D and SG&A Spending: R&D expenses of $126.6M and SG&A of $163.9M in Q1 2026 far exceed revenue, leading to an operating margin of -113.3%. The company's reliance on continued investment to fuel growth leaves little room for error in execution.
- Competitive Threats in ATTR-CM Market: Attruby faces competition from established players like Pfizer's Vyndamax and Alnylam's Amvuttra, which have strong market presence. If Attruby fails to gain significant market share, revenue growth could decelerate, undermining the bullish thesis.
BBIO Technical Analysis
BridgeBio's stock is in a strong uptrend, with a 1-year price change of +62.25%, significantly outperforming the S&P 500's +20.48% over the same period. The current price of $81.50 sits at 78.4% of the 52-week range (low $46.81, high $93.415), indicating the stock is trading near its highs, reflecting robust momentum but also potential overextension. The 6-month change of +19.61% and 3-month change of +17.91% confirm the sustained upward trajectory, with the stock recently pulling back from its July peak of $90.17.
Beta
0.98
0.98x market volatility
Max Drawdown
-20.3%
Largest decline past year
52-Week Range
$47-$93
Price range past year
Annual Return
+62.3%
Cumulative gain past year
| Period | BBIO Return | S&P 500 |
|---|---|---|
| 1m | -1.4% | +3.6% |
| 3m | +17.9% | +2.7% |
| 6m | +19.6% | +11.4% |
| 1y | +62.3% | +18.7% |
| ytd | +4.2% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BBIO Fundamental Analysis
BridgeBio's revenue is growing rapidly, with Q1 2026 revenue of $194.5 million, up 66.8% year-over-year, driven primarily by Attruby product sales of $180.6 million, which now dominate the mix. The company remains unprofitable, with a net loss of $164.0 million in Q1 2026, though the net margin improved to -84.3% from -143.5% in Q1 2025, reflecting operating leverage. Gross margin is exceptionally high at 94.6%, typical for biotech with low cost of goods, but operating margin is deeply negative at -113.3%, as R&D expenses of $126.6 million and SG&A of $163.9 million continue to outpace revenue.
Quarterly Revenue
$194515000.0B
2026-03
Revenue YoY Growth
+66.8%
YoY Comparison
Gross Margin
94.6%
Latest Quarter
Free Cash Flow
$-454120000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BBIO Overvalued?
Given BridgeBio's negative net income, the price-to-sales (PS) ratio is the primary valuation metric, currently at 30.05x trailing, which is elevated but justified by the company's high growth and large market opportunity. The forward PE of 532.05x is not meaningful due to near-term losses, but the EV/Sales of 26.47x provides a more conservative view. Compared to the biotech industry average PS of around 5-10x, BridgeBio trades at a significant premium, reflecting its commercial-stage status and pipeline potential, though this premium is risky if growth decelerates.
PE
-20.2x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-25.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are substantial: BridgeBio reported a net loss of $164.0M in Q1 2026, with negative free cash flow of -$454M TTM. The company's debt-to-equity ratio is -1.31, indicating negative equity, which raises solvency concerns. However, the current ratio of 2.62 suggests adequate short-term liquidity, but continued losses require frequent capital raises, potentially diluting existing shareholders. The high gross margin of 94.6% is offset by operating margin of -113.3%, showing that R&D and SG&A costs are far outpacing revenue generation, and any delay in achieving profitability could strain the balance sheet.
Market and competitive risks are equally significant. The stock trades at a PS ratio of 30.05x, far above the biotech industry average, making it vulnerable to valuation compression if growth expectations are not met. The ATTR-CM market is competitive, with Pfizer and Alnylam offering established treatments, and BridgeBio must differentiate Attruby to gain share. Additionally, the stock's beta of 0.983 indicates high correlation with the market, so a broad market downturn could amplify losses. Regulatory risks include potential delays in FDA approval for the achondroplasia program, which is a key catalyst, and any negative trial data could severely impact the stock.
In a worst-case scenario, if Attruby sales growth stalls, the achondroplasia program fails to gain approval, and the company faces a capital crunch, the stock could fall to its 52-week low of $46.81, representing a -42.6% decline from the current price of $81.50. This scenario would likely involve a combination of missed revenue targets, increased competition, and a broader biotech selloff, leading to a sharp de-rating. Given the stock's historical max drawdown of -20.25%, a more moderate downside of -20% to $65.20 is plausible, but the binary nature of pipeline events could amplify losses.
FAQ
The key risks of holding BBIO include financial risks such as persistent net losses and negative free cash flow, which could lead to dilution through capital raises. Competitive risks are also significant, as Attruby faces competition from established drugs like Pfizer's Vyndamax and Alnylam's Amvuttra. Regulatory risks include potential delays or failures in the achondroplasia program, which is a major catalyst. Macro risks include the stock's high beta of 0.983, making it sensitive to market downturns. The most severe risk is a combination of these factors leading to a sharp decline, potentially to the 52-week low of $46.81, representing a 42.6% loss from current levels.
The BBIO stock forecast over the next 12 months is bullish, with a base case target of $108.43 (33% upside) and a bull case target of $157 (92.6% upside). The bear case target is $80, near the current price, with a probability of 20%. The most likely scenario is the base case, assuming Attruby sales continue to grow and the achondroplasia program progresses as planned. The stock's performance will heavily depend on quarterly earnings and FDA news. If the company meets or exceeds expectations, the stock could reach the higher targets; if not, it could fall to the lower end of the range.
BBIO is trading at a PS ratio of 30.05x, which is significantly higher than the biotech industry average of 5-10x, indicating a premium valuation. This premium is justified by the company's rapid revenue growth of 66.8% YoY and its high gross margin of 94.6%. However, the forward PE of 532x is not meaningful due to near-term losses. Compared to its own history, the stock is trading near the high end of its valuation range, reflecting high market expectations. The market is pricing in continued strong growth and successful pipeline execution. If these expectations are met, the stock is fairly valued; if not, it could be overvalued and subject to correction.
BBIO is a good buy for investors with a high risk tolerance and a long-term horizon, given its strong revenue growth and promising pipeline. The stock has a consensus Strong Buy rating with an average target price of $108.43, implying 33% upside from the current $81.50. However, the high PS ratio of 30.05x and persistent net losses make it a risky investment. The biggest downside risk is a slowdown in Attruby sales or pipeline failures, which could lead to a significant decline. For those who believe in the company's growth story and can withstand volatility, BBIO offers substantial upside potential, but it is not suitable for conservative investors.
BBIO is more suitable for long-term investment due to its high volatility and binary catalysts. The stock has a beta of 0.983, indicating high market correlation, and a short interest ratio of 6.98, which can lead to sharp price swings. Short-term trading is possible but risky, as the stock can move significantly on news. For long-term investors, the company's growth potential in the ATTR-CM market and pipeline expansion offer substantial upside over a 3-5 year horizon. The company is not yet profitable, so investors should be prepared for continued losses and potential dilution. A minimum holding period of 3 years is recommended to allow the pipeline to mature and the company to approach profitability.